HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

ETC-588 (Pfizer).

Abstract
Pfizer, following its acquisition of Esperion Therapeutics in the first quarter of 2004, is developing ETC-588 as a potential acute treatment for ischemia caused by atherosclerosis. Enrollment in phase II trials in patients with acute coronary syndrome is complete.
AuthorsSheila A Doggrell
JournalCurrent opinion in investigational drugs (London, England : 2000) (Curr Opin Investig Drugs) Vol. 5 Issue 9 Pg. 993-9 (Sep 2004) ISSN: 1472-4472 [Print] England
PMID15503656 (Publication Type: Journal Article, Review)
Chemical References
  • Cardiovascular Agents
  • Phosphatidylcholines
  • 1-oleoyl-2-palmitoylphosphatidylcholine
Topics
  • Animals
  • Cardiovascular Agents (adverse effects, pharmacokinetics, therapeutic use)
  • Cardiovascular Diseases (drug therapy)
  • Humans
  • Phosphatidylcholines (adverse effects, pharmacokinetics, therapeutic use)
  • Randomized Controlled Trials as Topic

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: